Cancer Immunotherapy

NeoVac’s LNP platform can specifically deliver LNPs to antigen-presenting cells for cancer immunotherapy

Conventional mRNA–LNPs lack targeting specificity, leading to safety risks and reduced efficacy

1. Antigen Presenting Cells: Key mediators of immune response, which can recognize tumor antigens and be harnessed for anti-cancer immunotherapy

2. Existing mRNA-LNPs have limitations: Conventional mRNA–LNPs show poor targeting, causing reduced efficacy and safety risks due to off-target cargo release and toxicity

Shingles